Chemicon and Axordia to Co-Develop Antibody Markers
News Oct 03, 2005
Serologicals Corporation has announced that Chemicon International, Inc., its wholly-owned subsidiary, and Axordia Ltd. have signed an exclusive agreement to co-develop antibody markers from Axordia's proprietary human embryonic stem (ES) cell lines.
Under the terms of this agreement, Axordia will contribute proprietary expertise and materials for antibody generation and antibody characterization and Chemicon will commercialize the antibody research tools arising from this collaboration.
Through this agreement, Chemicon will be able to supply antibody markers to the worldwide ES cell research community.
“Chemicon is pleased to be entering into this exclusive collaborative agreement with Axordia, and its world class scientists, in the stem cell marker field,” said Jeffrey D. Linton, President of Chemicon.
“This Agreement will allow us to expand our successful portfolio of stem cell antibody reagents.”
“New antibodies resulting from this exclusive collaboration will increase the inventive process already being provided by Chemicon to thousands of human ES cell researchers worldwide.”
“In addition, we look forward to furthering our collaboration with Axordia to co-develop and market additional innovative human ES cell products,” stated Mr. Linton.
“Axordia believes that antibodies along with other key discovery technologies will be crucial in enabling stem cells to deliver their full potential to palliate and cure some of the most debilitating diseases,” said Dr. V. Paul Gerskowitch, CEO of Axordia.
“Our partnership with a market leader in research and drug discovery tools represents a powerful step in bringing this potential forward and is recognition of our world class expertise in developing the tools needed to make the promise of stem cell technology a reality.”